Note: This webinar took place on the 07/07/2016. You can find a video recording and the presentation used during the webinar below.
How early in the development of a new medicine should thEarly collaboration – a recipe for solutions: drug development and treatment strategies may go hand in hand.e discussion between researchers and patients occur? Can such early strategic interaction really maximize the value of the outcome? In this EUPATI webinar, a pharmaceutical industry researcher and a patient expert will present two cases describing the research questions, their interaction and the outcome of this early collaboration. Join us in listening and discussing two very interesting experiences of successful patient involvement in the development of new medicines.
|17:00||Welcome and introductions
Ingrid Klingmann, EFGCP
|17:10||“2 New Chemical Entities”
Problem description: David Haerry, EATG & EUPATI Consortium Member
Challenges implementing such a study: Brian Woodfall, Janssen
Multidrug resistance today: David Haerry, EATG & EUPATI Consortium Member
|17:25||Q & A – Moderator: Ingrid Klingmann, EFGCP|
Discovery and questions to advisors at early stage: Brian Woodfall, Janssen
Responding to scenario questions about a distant reality: David Haerry, EATG & EUPATI Consortium Member
Current development status nano suspension: Brian Woodfall, Janssen
|18:05||Q & A – Moderator: Ingrid Klingmann, EFGCP|
|18:30||Close of the Webinar|
Presentation title: Early collaboration – a recipe for solutions: drug development and treatment strategies may go hand in hand.
- Ingrid Klingmann, Chairman at European Forum for Good Clinical Practice (EFGCP)
- David Haerry, EATG & EUPATI Consortium Member
- Brian Woodfall, Janssen